WO2000022166A3 - Genes for assessing cardiovascular status and compositions for use thereof - Google Patents

Genes for assessing cardiovascular status and compositions for use thereof Download PDF

Info

Publication number
WO2000022166A3
WO2000022166A3 PCT/IB1999/001678 IB9901678W WO0022166A3 WO 2000022166 A3 WO2000022166 A3 WO 2000022166A3 IB 9901678 W IB9901678 W IB 9901678W WO 0022166 A3 WO0022166 A3 WO 0022166A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
cardiovascular status
genes
compositions
adrenoceptor
Prior art date
Application number
PCT/IB1999/001678
Other languages
French (fr)
Other versions
WO2000022166A2 (en
Inventor
Leif Torbjorn Norberg
Maria Kristina Andersson
Per Harry Rutger Lindstrom
Lena Jonsson
Original Assignee
Pyrosequencing Ab
Leif Torbjorn Norberg
Maria Kristina Andersson
Per Harry Rutger Lindstrom
Lena Jonsson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pyrosequencing Ab, Leif Torbjorn Norberg, Maria Kristina Andersson, Per Harry Rutger Lindstrom, Lena Jonsson filed Critical Pyrosequencing Ab
Priority to AU61163/99A priority Critical patent/AU6116399A/en
Priority to EP99947799A priority patent/EP1121462A2/en
Priority to JP2000576056A priority patent/JP2002527079A/en
Priority to IL14254899A priority patent/IL142548A0/en
Priority to CA002347247A priority patent/CA2347247A1/en
Publication of WO2000022166A2 publication Critical patent/WO2000022166A2/en
Publication of WO2000022166A3 publication Critical patent/WO2000022166A3/en
Priority to NO20011847A priority patent/NO20011847L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • C12N9/0079—Steroid 11 beta monooxygenase (P-450 protein)(1.14.15.4)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • C12N9/6486—Renin (3.4.23.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/23—Aspartic endopeptidases (3.4.23)
    • C12Y304/23015—Renin (3.4.23.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides methods for assessing cardiovascular status in an individual, which comprise determining the sequence at one or more polymorphic positions within the human genes encoding ACE, AT1, AGT, renin, aldosterone synthase, type-2 angiotensin II receptor, endothelin receptor, and β-adrenoceptor. The invention also provides isolated nucleic acids encoding polymorphisms in genes encoding ACE, AT1, AGT, renin, aldosterone synthase, type-2 angiotensin II receptor, endothelin receptor and β-adrenoceptor, nucleic acid probes that hybridized to polymorphic positions, kits for the prediction of cardiovascular status, and nucleic acid and peptide targets for use in identifying candidate cardiovascular drugs.
PCT/IB1999/001678 1998-10-14 1999-10-13 Genes for assessing cardiovascular status and compositions for use thereof WO2000022166A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU61163/99A AU6116399A (en) 1998-10-14 1999-10-13 Genes for assessing cardiovascular status and compositions for use thereof
EP99947799A EP1121462A2 (en) 1998-10-14 1999-10-13 Genes for assessing cardiovascular status and compositions for use thereof
JP2000576056A JP2002527079A (en) 1998-10-14 1999-10-13 Genes for assessing cardiovascular status and compositions for their use
IL14254899A IL142548A0 (en) 1998-10-14 1999-10-13 Genes for assessing cardiovascular status and compositions for use thereof
CA002347247A CA2347247A1 (en) 1998-10-14 1999-10-13 Genes for assessing cardiovascular status and compositions for use thereof
NO20011847A NO20011847L (en) 1998-10-14 2001-04-10 Genes for assessing cardiovascular status and compositions for its use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10430298P 1998-10-14 1998-10-14
US10428698P 1998-10-14 1998-10-14
US60/104,286 1998-10-14
US60/104,302 1998-10-14

Publications (2)

Publication Number Publication Date
WO2000022166A2 WO2000022166A2 (en) 2000-04-20
WO2000022166A3 true WO2000022166A3 (en) 2000-09-14

Family

ID=26801367

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1999/001678 WO2000022166A2 (en) 1998-10-14 1999-10-13 Genes for assessing cardiovascular status and compositions for use thereof

Country Status (7)

Country Link
EP (1) EP1121462A2 (en)
JP (1) JP2002527079A (en)
AU (1) AU6116399A (en)
CA (1) CA2347247A1 (en)
IL (1) IL142548A0 (en)
NO (1) NO20011847L (en)
WO (1) WO2000022166A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19938390A1 (en) * 1999-08-05 2001-03-08 Max Delbrueck Centrum New sequence variants of the human ßl adrenoceptor gene and their use
US20030124524A1 (en) * 2000-06-23 2003-07-03 Kenneth Kornman Screening assays for identifying modulators of the inflammatory or immune response
US20030113726A1 (en) * 2000-12-04 2003-06-19 Zenta Tsuchihashi Human single nucleotide polymorphisms
DE10065666B4 (en) * 2000-12-29 2008-10-02 Wiesner, Rudolf, Prof. Dr. DNA chip for the causal diagnosis of hypertension
WO2002063045A1 (en) * 2001-02-02 2002-08-15 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the angiotensin receptor 2 gene
EP1394267A1 (en) * 2002-08-19 2004-03-03 Bayer HealthCare AG Single nucleotide polymorphisms predictive for cardiovascular disease, adverse drug reactions, and drug efficacy
JP4502570B2 (en) * 2002-09-24 2010-07-14 株式会社東洋紡ジーンアナリシス IgA nephropathy diagnosis using genetic polymorphism analysis and IgA nephropathy diagnosis kit
ATE469245T1 (en) 2004-09-14 2010-06-15 Univ Colorado GENETIC TARGETING-BASED METHOD FOR TREATMENT WITH BUCINDOLOL
EP1851329B1 (en) 2005-02-02 2012-06-20 The Royal College of Surgeons in Ireland Pharmacogenomics of blood pressure lowering agents
BRPI0609702A2 (en) * 2005-03-22 2010-04-20 Novartis Ag biomarkers for the efficacy of aliskiren as a hypertensive agent
WO2007008604A2 (en) * 2005-07-08 2007-01-18 Bristol-Myers Squibb Company Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
CA2729640A1 (en) 2008-07-03 2010-01-07 Mor Research Applications Ltd Diagnostic polymorphisms for cardiac disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002709A1 (en) * 1985-10-24 1987-05-07 Biotechnology Research Partners, Ltd. Blood tests diagnostic for hypertension
WO1988008457A1 (en) * 1987-04-30 1988-11-03 Biotechnology Research Partners, Ltd. Hypertension-related blood tests useful as genetic markers
US5580722A (en) * 1989-07-18 1996-12-03 Oncogene Science, Inc. Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
WO1998045477A2 (en) * 1997-04-04 1998-10-15 Eurona Medical Ab Methods for assessing cardiovascular status and compositions for use thereof
WO1999037761A1 (en) * 1997-12-30 1999-07-29 Max-Delbrück-Centrum für Molekulare Medizin Novel sequence variants of the human beta2-adrenergic receptor gene and use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002709A1 (en) * 1985-10-24 1987-05-07 Biotechnology Research Partners, Ltd. Blood tests diagnostic for hypertension
WO1988008457A1 (en) * 1987-04-30 1988-11-03 Biotechnology Research Partners, Ltd. Hypertension-related blood tests useful as genetic markers
US5580722A (en) * 1989-07-18 1996-12-03 Oncogene Science, Inc. Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
WO1998045477A2 (en) * 1997-04-04 1998-10-15 Eurona Medical Ab Methods for assessing cardiovascular status and compositions for use thereof
WO1999037761A1 (en) * 1997-12-30 1999-07-29 Max-Delbrück-Centrum für Molekulare Medizin Novel sequence variants of the human beta2-adrenergic receptor gene and use thereof

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
BIOGENIC AMINES 1995, vol. 11, no. 4, 1995, pages 313 - 324, ISSN: 0168-8561 *
BONNARDEAUX A ET AL: "ANGIOTENSIN II TYPE 1 RECEPTOR GENE POLYMORPHISMS IN HUMAN ESSENTIAL HYPERTENSION", HYPERTENSION,XX,XX, vol. 24, no. 1, July 1994 (1994-07-01), pages 63 - 69, XP000862817, ISSN: 0194-911X *
CAMBIEN F ET AL: "DELETION POLYMORPHISM IN THE GENE FOR ANGIOTENSIN-CONVERTING ENZYME IS A POTENT RISK FACTOR FOR MYOCARDIAL INFARCTION", NATURE,GB,MACMILLAN JOURNALS LTD. LONDON, vol. 359, 15 October 1992 (1992-10-15), pages 641 - 644, XP000619624, ISSN: 0028-0836 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1995, FROSSARD P M ET AL: "Correlations between RFLPs of the human renin gene locus and clinical variables of blood pressure regulation.", XP002137266, Database accession no. PREV199598451934 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; August 1998 (1998-08-01), BRAND EVA ET AL: "Structural analysis and evaluation of the aldosterone synthase gene in hypertension.", XP002137265, Database accession no. PREV199800429752 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; June 1998 (1998-06-01), TIMMERMANN BERND ET AL: "beta-2 Adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: The bergen blood pressure study.", XP002137264, Database accession no. PREV199800302947 *
HYPERTENSION (DALLAS) AUG., 1998, vol. 32, no. 2, August 1998 (1998-08-01), pages 198 - 204, ISSN: 0194-911X *
JEUNEMAITRE X ET AL: "HAPLOTYPES OF ANGIOTENSINOGEN IN ESSENTIAL HYPERTENSION", AMERICAN JOURNAL OF HUMAN GENETICS,US,NEW YORK, NY, vol. 60, June 1997 (1997-06-01), pages 1448 - 1460, XP000857377, ISSN: 0002-9297 *
JEUNEMAITRE X ET AL: "MOLECULAR BASIS OF HUMAN HYPERTENSION: ROLE OF ANGIOTENSINOGEN", CELL, 2 October 1992 (1992-10-02), XP002063176 *
KAMITANI ET AL.: "Significance of te angiotensinogen gene polymorphism as a risk factor for myocardial infarction in the japanese", HYPERTENSION, vol. 24, 1994, pages 381, XP000906933 *
KIDNEY INTERNATIONAL JUNE, 1998, vol. 53, no. 6, June 1998 (1998-06-01), pages 1455 - 1460, ISSN: 0085-2538 *
SOUBRIER F ET AL: "RENIN-ANGIOTENSIN SYSTEM GENES AS CANDIDATE GENES IN CARDIOVASCULARDISEASES", TRENDS IN CARDIOVASCULAR, 1 January 1993 (1993-01-01), XP002063177 *
TIRET L ET AL: "SYNERGISTIC EFFECT OF ANGIOTENSIN-CONVERTING ENZYME AND ANGIOTENSIN-II TYPE 1 RECEPTOR GENE POLYMORPHISMS ON RISK OF MYOCARDIAL INFARCTION", LANCET THE,GB,LANCET LIMITED. LONDON, vol. 344, 1 October 1994 (1994-10-01), pages 910 - 913, XP000619739, ISSN: 0140-6736 *

Also Published As

Publication number Publication date
NO20011847L (en) 2001-06-14
JP2002527079A (en) 2002-08-27
NO20011847D0 (en) 2001-04-10
CA2347247A1 (en) 2000-04-20
IL142548A0 (en) 2002-03-10
EP1121462A2 (en) 2001-08-08
WO2000022166A2 (en) 2000-04-20
AU6116399A (en) 2000-05-01

Similar Documents

Publication Publication Date Title
WO2001013086A3 (en) Detection of nucleic acids
WO1998045477A3 (en) Methods for assessing cardiovascular status and compositions for use thereof
WO2000022166A3 (en) Genes for assessing cardiovascular status and compositions for use thereof
WO2007027867A3 (en) Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
JP5091163B2 (en) Methods and kits for early detection of cancer or its predisposition
WO2007053245A3 (en) Methods and composition to generate unique sequence dna probes, iabeling of dna probes and the use of these probes
WO2002048310A3 (en) Methods and compositions for diagnosing and treating rheumatoid arthritis
DK0805876T3 (en) Nucleic acid amplification oligonucleotides and probes for Lyme disease-associated Borrelia
WO2002018638A3 (en) Detection of cyp2d6 polymorphisms
WO2005047543A3 (en) Ligation assay
EP1965213A3 (en) Microarrays and uses therefor
WO2005007869A3 (en) Assays for the direct measurement of gene dosage
WO2007027957A3 (en) Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2007027906A3 (en) Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2003027328A3 (en) Methods, kits and compositions pertaining to the suppression of detectable probe binding to randomly distributed repeat sequences in genomic nucleic acid
GB2401433A (en) Methods of parallel gene cloning and analysis
WO2006086111A3 (en) Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2003072828A3 (en) Fcgammariib polymorphisms detection in system lupus erythematosus
WO2007127335A3 (en) Reagents for the detection of protein phosphorylation in atm and atr kinase signaling pathways
WO2003014388A3 (en) Method and nucleic acids for the analysis of colon cancer
ATE449868T1 (en) METHODS, TEST SETS AND COMPOSITIONS FOR DETECTING AND QUANTIFYING TARGET SEQUENCES
WO1996039511A3 (en) A c5a-like seven transmembrane receptor
WO2006060595A3 (en) Reverse two hybrid system for identification of interaction domains
WO2001040522A3 (en) Short shared nucleotide sequences
WO2001007579A3 (en) Methods and compositions for determining enzymatic activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 142548

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2347247

Country of ref document: CA

Ref country code: CA

Ref document number: 2347247

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 576056

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 511135

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1999947799

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 61163/99

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1999947799

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642